Zacks Research Comments on Novavax FY2027 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Equities research analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Novavax in a research note issued on Thursday, March 20th. Zacks Research analyst S. Ganoria expects that the biopharmaceutical company will post earnings of $0.54 per share for the year. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million for the quarter, compared to the consensus estimate of $85.48 million. During the same quarter in the previous year, the firm posted ($1.44) earnings per share.

NVAX has been the topic of a number of other reports. BTIG Research initiated coverage on Novavax in a research note on Friday, February 28th. They set a “buy” rating and a $19.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $19.00 price objective on shares of Novavax in a research note on Tuesday, December 10th. Finally, TD Cowen upgraded Novavax to a “hold” rating in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $18.00.

Novavax Stock Performance

NASDAQ:NVAX opened at $7.60 on Monday. Novavax has a 52-week low of $3.81 and a 52-week high of $23.86. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -3.36, a PEG ratio of 2.85 and a beta of 2.92. The business’s fifty day moving average is $8.25 and its 200 day moving average is $9.49.

Insiders Place Their Bets

In other news, Director James F. Young sold 5,400 shares of the company’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total value of $43,200.00. Following the completion of the transaction, the director now directly owns 51,760 shares in the company, valued at approximately $414,080. This represents a 9.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.00% of the company’s stock.

Hedge Funds Weigh In On Novavax

Hedge funds and other institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new position in shares of Novavax in the 4th quarter worth about $27,000. Spire Wealth Management purchased a new position in shares of Novavax in the 4th quarter worth about $29,000. New Age Alpha Advisors LLC purchased a new position in shares of Novavax in the 4th quarter worth about $35,000. KBC Group NV boosted its holdings in shares of Novavax by 97.0% in the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 3,917 shares in the last quarter. Finally, TigerOak Management L.L.C. purchased a new position in shares of Novavax in the 4th quarter worth about $86,000. 53.04% of the stock is currently owned by hedge funds and other institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.